DCF Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
DCF Advisers's VRTX Position: Q2 2026 in Review
DCF Advisers increased its Vertex Pharmaceuticals (VRTX) stake by 64% in Q2 2026, buying an estimated $1.99M and bringing the position to 11,500 shares worth $5.71M. The position accounts for 1.01% of the portfolio, ranked #17.
DCF Advisers first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- DCF Advisers held 11,500 shares of Vertex Pharmaceuticals worth $5.71M as of Q2 2026.
- DCF Advisers bought 4,500 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.99M.
- Vertex Pharmaceuticals made up 1.01% of DCF Advisers's portfolio in Q2 2026, its #17 holding.
- DCF Advisers first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.